Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis identifier:
NCT03317392 (

People with castration-resistant prostate cancer with bone spread

Study Contact Information:

Contact:  Rana R McKay  858-822-5354 or by email: [email protected]        

About the Study

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones

Type of Study


This is a randomized study with two separate treatment groups.      

Participants are placed into one of two study groups by chance, and neither the participants nor the researchers choose the group into which the participants are placed.

The study allows crossover. Participants in Group 2 whose cancer gets worse will be allowed to switch to Group 1 and receive olaparib.

What the Study Involves

Study Sites





New Jersey




This Study is Open To:

People age 18 years or older who meet all of the following criteria*:

*Contact your doctors or the study coordinators for a complete list of inclusion criteria.

This Study is Not Open To:

This study is not open to those who have*:

*Contact your doctors or the study coordinators for a complete list of exclusion criteria.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.